A comparison of the efficacy of two commercial Aujeszky's disease vaccines with glycoprotein-I deletion in pigs

Two commercial Aujeszky's disease vaccines, a modified killed vaccine and a sub-unit vaccine, both carrying a deletion of glycoprotein-I, were evaluated in pigs. Each vaccine was administered to two groups of four pigs, twice at 4-week intervals, with two pigs held as unvaccinated controls. All pigs were challenged with a New Zealand field isolate of Aujeszky's disease virus 3 weeks after the second vaccination. The results indicate that the sub-unit vaccine was able to protect pigs against clinical Aujeszky's disease much better than the pigs vaccinated with the modified killed vaccine when challenged with a virulent virus. However, the amount and the duration of virulent virus excretion following challenge was greater with the sub-unit vaccine than the modified killed vaccine. Pigs vaccinated with the sub-unit vaccine were shown to be latently infected following challenge. Latent infection was demonstrated by excretion of Aujeszky's disease virus from the nasal cavity after dexamethasone treatment and seroconversion of a sentinel in contact pigs to Aujeszky's disease virus.     

gIII antibody responses in pigs following vaccination and challenge to Aujeszky's disease.

Serological responses to a genetically engineered Aujeszky's disease "marker" vaccine (dl gIII + dl tk) were monitored using a blocking-ELISA (B-ELISA), a serum neutralisation test (SNT) and an indirect ELISA (I-ELISA). The B-ELISA is capable of differentiating pigs vaccinated with the above vaccine from natural infection. The SNT and the I-ELISA indicated that the pigs responded to vaccination and challenge. All three tests showed that the controls and the in-contact pigs always reacted negative for antibodies. The B-ELISA was able to detect pigs challenged with a field isolate 24 days post-challenge. These pigs remained positive until 110 days post-challenge when last tested. These findings indicate that the B-ELISA could be used successfully with this vaccine in a control eradication programme. This trial also shows that the vaccine virus did not spread to the in-contact pigs and also the vaccinated and challenged pigs did not transmit the disease to other susceptible pigs when they were introduced 14 days after challenge.     

Nutritional management of horses competing in 160 km races

A survey was taken of dietary management and training schedules of 54 horses competing in two 160 km endurance races. A total of 52 owners, representing 54 horses, responded to a questionnaire distributed prior to the races. Diet and training schedules were compared between horses that successfully completed the races and those that were eliminated for metabolic reasons. Horses that completed the races were 11.5 +/- 4 years old, weighed 429 +/- 4.5 kg and were ridden 61 +/- 32 km a week when training. Feed intake was reported as "free choice hay or pasture" by 34 of the respondents. Dry matter (DM) hay intake in these horses was estimated to be 3% body weight (kg) minus the kg DM of grain fed, assuming a maximum intake. They were fed 12.3 +/- 2.3 kg feed per day consisting of 10 +/- 2.3 kg hay and 2.3 +/- 1.4 kg of grain. Most had free access to salt and were fed 1 +/- 1 vitamin/mineral supplement per day. Based on Nutritional Research Council (NRC) values for nutrient content of the reported feeds, diets contained 60 +/- 5% total digestible nutrients (TDN), 12 +/- 2% crude protein, 27 +/- 4% crude fiber, 0.72 +/- 0.4% calcium and 0.29 +/- 0.06% phosphorus. Maximum caloric intake was estimated to be 31.9 Mcal per day. Ratios of nutrients fed per kilometer trained were: kg TDN/km = .14 +/- .08, kg crude protein/km trained = .03 +/- .02, and kg crude fiber/km trained = .06 +/- .04.(ABSTRACT TRUNCATED AT 250 WORDS)     

Use of an inhibitor typing scheme to study the epidemiology of Streptococcus uberis mastitis

An inhibitor typing scheme, based on the production of and sensitivity to bacteriocin-like inhibitor substances was used to identify strains of Streptococcus uberis obtained from skin swabs and milk samples of dairy cows. Thirty-nine isolates from one herd were compared, with one isolate examined per site for any sampling day. Eighteen different inhibitor profiles were observed from these isolates. When several isolates were obtained from various skin sites on a cow on the same day, the inhibitor profiles were all different. In three cases, Str. uberis was simultaneously isolated from milk sample and teat surface of the same quarter, but similar inhibitor profiles were only observed for one pair of isolates. Furthermore, when several isolates were obtained by repeated swabbing of a single skin site on a cow on the same day, differences in the inhibitor profiles were again seen. It is likely that numerous strains of Str. uberis are capable of producing clinical mastitis since a comparison of ten isolates obtained from cases of clinical mastitis revealed eight different inhibitor profiles. Monthly sampling (April-November) of eleven cows revealed that Str. uberis could be isolated from the skin of the abdominal wall, medial thigh, udder and teats, but was not isolated from the rectum of any of the cows. Str. uberis was more frequently isolated from the skin and milk samples during the winter when the cows had been dried off, than during the spring and autumn.     

Thalidomide pharmacokinetics in sheep

AIM: To determine the half life (T_1/2), time taken to reach maximum plasma concentration (T_max) and maximum plasma concentration (C_max) of thalidomide in sheep following I/V, oral and topical treatment with a single dose of thalidomide.

METHOD: Three groups of 4–6-month-old ram lambs were treated with thalidomide dissolved in dimethylsulphoxide (DMSO). The first group (n=10) was treated I/V with 100?mg thalidomide in 2?mL DMSO; the second group (n=8) received 400?mg thalidomide in 2?mL DMSO orally, and the third group (n=8) had 400?mg thalidomide in 4?mL DMSO applied topically. Plasma samples were collected up to 36 hours after treatment, snap-frozen at ?80°C and analysed for concentrations of thalidomide using high performance liquid chromatography.

RESULTS: Following I/V administration, T_1/2 was 5.0 (SEM 0.4) hours, volume of distribution was 3,372.0 (SEM 244.3) mL/kg and clearance was 487.1 (SEM 46.1) mL/hour.kg. Topical application of 400?mg thalidomide did not increase plasma concentrations. Following oral administration, thalidomide bioavailability was 89%, with T_1/2, T_max, and C_max being 7.2 (SEM 0.8) hours, 3.0 (SEM 0.4) hours and 1,767.3 (SEM 178.1) ng/mL, respectively.

CONCLUSION: Topical administration using DMSO as a solvent did not increase concentrations of thalidomide in plasma. The mean pharmacokinetic parameters determined following oral treatment with 400?mg of thalidomide were similar to those reported in humans receiving a single 400?mg oral dose (T_1/2 7.3 hours; T_max 4.3 hours and C_max 2,820?ng/mL). There is potential for thalidomide to be used as a model for the treatment of chronic inflammatory conditions in sheep, such as Johne's disease, where tumour necrosis factor alpha plays a pathogenic role.     

Bilateral Sertoli and Interstitial Cell Tumours in Abdominal Testes of a Goat with Polled Intersex Syndrome (PIS)

An 8‐year‐old, mixed breed, polled goat was presented for evaluation of male‐like behaviour. Clinical findings included clitoromegaly, a heavily muscled neck, pronounced beard, and erect dorsal guard hairs, which are phenotypic characteristics commonly observed in intersex animals. Transrectal ultrasonography revealed the presence of two abdominal masses caudolateral to the uterine horns. Serum concentration of estradiol was elevated. Genetic evaluation was compatible with polled intersex syndrome defined by an XX karyotype without a Y chromosome or SRY gene. Based on gross and histologic evaluation, the abdominal masses were determined to be intra‐abdominal testes, each of which was effaced by Sertoli cell and interstitial (Leydig) cell tumours. The Sertoli cell tumours (SCTs) represented two unique histologic patterns. Regardless of pattern, neoplastic Sertoli cells were consistently lipid laden and positive for vimentin. Interstitial cell tumours (ICTs) were negative for vimentin. Clinical and histopathologic findings suggest that prolonged exposure to steroids secreted by neoplastic Sertoli cells contributed to virilization. In addition, results from immunohistochemistry indicated that vimentin may be a valuable immunodiagnostic tool for differentiation between interstitial and Sertoli cell tumours in goats.